These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15380337)

  • 61. [Genomic imprinting of insulin-like growth factor II in prostate cancer and its clinical significance].
    Liu ZW; Zhou FJ; Luo YM; Qin ZK; Wang DJ; Luo JH; Han H; Li YH; Wang H
    Ai Zheng; 2006 Jun; 25(6):765-70. PubMed ID: 16764778
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    Nielsen I; Hasselbalch HC
    Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The chronic Philadelphia chromosome-negative myeloproliferative syndrome II. Clinical findings, diagnostics and treatment].
    Hasselbalch HC; Mourits-Andersen HT; Jensen BA; Jensen MK; Nielsen OJ
    Ugeskr Laeger; 2001 Apr; 163(18):2474-7. PubMed ID: 11379260
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Megakaryopoiesis in chronic myeloproliferative disorders: immunohistochemical evaluation of endoreduplicative activity by PCNA-staining reaction.
    Thiele J; Titius BR; Kvasnicka HM; Rechmeier W; Fischer R
    Anal Cell Pathol; 1994 Jul; 7(1):63-75. PubMed ID: 7981137
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.
    Mertens F; Johansson B; Heim S; Kristoffersson U; Mitelman F
    Leukemia; 1991 Mar; 5(3):214-20. PubMed ID: 2013980
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera.
    Lawler SD
    Clin Haematol; 1980 Feb; 9(1):159-74. PubMed ID: 6768481
    [No Abstract]   [Full Text] [Related]  

  • 69. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
    [TBL] [Abstract][Full Text] [Related]  

  • 70. von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders.
    Chuang SS; Jung YC; Li CY
    Am J Clin Pathol; 2000 Apr; 113(4):506-11. PubMed ID: 10761451
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders.
    Bock O; Schlué J; Kreipe H
    Leukemia; 2003 Apr; 17(4):815-6. PubMed ID: 12682647
    [No Abstract]   [Full Text] [Related]  

  • 72. Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases.
    Panteli K; Bai M; Hatzimichael E; Zagorianakou N; Agnantis NJ; Bourantas K
    Hematology; 2007 Dec; 12(6):481-6. PubMed ID: 17852434
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Occurrence of myelofibrosis in individual types of chronic myeloproliferative diseases].
    Adamkov M; Plank L; Szépe P
    Bratisl Lek Listy; 1998 May; 99(5):240-4. PubMed ID: 9673037
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Megakaryocytes in chronic myeloproliferative disorders: numerical density correlated between different entities.
    Kaloutsi V; Fritsch RS; Buhr T; Restrepo-Specht I; Widjaja W; Georgii A
    Virchows Arch A Pathol Anat Histopathol; 1991; 418(6):493-7. PubMed ID: 2058083
    [TBL] [Abstract][Full Text] [Related]  

  • 75. DNA analysis to aid in the diagnosis of chronic myeloproliferative disorders.
    Kreipe H; Felgner J; Jaquet K; Heidorn K; Radzun HJ; Parwaresch R
    Am J Clin Pathol; 1992 Jul; 98(1):46-54. PubMed ID: 1615925
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation.
    Dalley A; Smith JM; Reilly JT; Neil SM
    Br J Haematol; 1996 Jun; 93(4):856-62. PubMed ID: 8703817
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Granulopoiesis in chronic myeloproliferative disorders (CMPD): electron microscopy/morphometric investigations].
    Fritsch RS; Maschek H; Ehlerding C; Widjaja W; Choritz H; Georgii A
    Verh Dtsch Ges Pathol; 1990; 74():216-9. PubMed ID: 1708587
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
    Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
    Ann Hematol; 2008 Jan; 87(1):1-10. PubMed ID: 17938925
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Epidemiologic features of Philadelphia-negative chronic myeloproliferative disorders in Szabolcs-Szatmár-Bereg county, Hungary. Analysis of data of a 33-year period].
    Jakó J; Szerafin L
    Orv Hetil; 2017 Apr; 158(15):572-578. PubMed ID: 28393599
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Histomorphometric study of megakaryocytes in bone marrow in selected myeloproliferative and lymphoproliferative diseases.
    Lemancewicz D; Dziecioł J; Kłoczko J; Litwiejko-Pietryńczak E; Bogusłowicz W
    Folia Morphol (Warsz); 2003 Feb; 62(1):51-6. PubMed ID: 12769178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.